Lupin Gets Namenda License In Forest Settlement

Law360, New York (December 22, 2009, 4:23 PM EST) -- Lupin Ltd. has received a license to begin selling a generic version of Forest Laboratories Inc.'s Namenda about four months before a patent for the lucrative Alzheimer's drug expires, as part of a settlement between the two companies, the Indian pharmaceutical maker said Monday.

Under the terms of the deal — which resolves all pending Hatch-Waxman Act litigation between the two over the drug — Lupin will have a license under the required patents to launch its generic memantine tablets in January 2015 or earlier in...
To view the full article, register now.